INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Vistagen Therapeutics, Inc. (VTGN) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Core Viewpoint - A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. alleging false and misleading statements regarding the risks associated with the Phase 3 PALISADE-3 trial of fasedienol [1] Group 1: Lawsuit Details - The lawsuit claims that Vistagen failed to disclose material adverse facts related to the risks of failure in its clinical trial [1] - The class action is aimed at shareholders who purchased Vistagen shares between April 1, 2024, and December 16, 2025, and experienced significant losses [2] Group 2: Legal Representation - Holzer & Holzer, LLC is representing the shareholders in this case and has a history of recovering hundreds of millions of dollars for investors affected by corporate misconduct [3] - The deadline for shareholders to be appointed as lead plaintiff in the case is March 16, 2026 [3]